Oral Oncology
Volume 39, Issue 7 , Pages 656-663, October 2003

Survival from glottic and supraglottic laryngeal carcinoma in Mumbai (Bombay), India

  • R Sankaranarayanan

      Affiliations

    • Unit of Descriptive Epidemiology, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08 France
    • Corresponding Author InformationCorresponding author. Tel.: +33-472-73-85-99; fax: +33-472-73-86-50
  • ,
  • Agnihotram V Ramanakumar

      Affiliations

    • Unit of Descriptive Epidemiology, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08 France
  • ,
  • Balakrishna B Yeole

      Affiliations

    • Bombay Cancer Registry, Indian Cancer Society, 74 Jerbai Wadia Road, Parel, Mumbai (Bombay) 400 012, India

Received 27 January 2003; accepted 17 March 2003.

Abstract 

The survival experience of patients with cancer of the larynx (ICD 10) registered by the Bombay population-based cancer registry India, during the years 1992–1994, is described. The vital status of these subjects were established by matching with death certificates from the Bombay Municipal death register and by active methods such as reply-paid postal enquiries, telephone enquiries, scrutiny of case records and house visits. Of the 675 eligible cases for analysis, 458 (67.9%) were dead and 217 (32.1%) were alive at last follow-up. The 5-year observed and relative survival rates were 29.1 and 38.2%, respectively; these were 52.1 and 58.5% for glottic laryngeal cancer and 24.2 and 31.4% for supraglottic laryngeal cancer, respectively. The 5-year observed survival was 53.1% for those with localised cancer and 17.8% for those with regional extension. Advancing age, regional and metastatic disease and supraglottic cancers were associated with significantly reduced survival. Early detection and prompt treatment should improve overall survival from laryngeal cancer.

Keywords:  Larynx, Glottic larynx, Supraglottic larynx, Treatment, Survival, Control

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-8375(03)00052-6

doi:10.1016/S1368-8375(03)00052-6

Oral Oncology
Volume 39, Issue 7 , Pages 656-663, October 2003